Review findings

Restore access No thanks, continue reading Related Reading Peptide Melanotan-2 melanocortin receptor agonist Peptide Melanotan-1 alpha-MSH analog for photoprotection Article Melanotan Tanning Peptides: Risks and Research Evidence How PT-141 works at the cellular level Overview of PT-141 benefits and applications Scientific Details Molecular Formula C50H68N14O10 Molecular Weight 1025.18 Da CAS Number 189691-06-3 Sequence Ac-Nle-c[Asp-His-D-Phe-Arg

Confirmed FDA approval for HSDD in premenopausal women On-demand dosing with 1.75 mg SC injection Clinical benefit maintained over treatment period Related Reading # PT-141 research studies and evidence PT-141 dosing protocols PT-141 side effects profile Bivamelagon research guide Gonadorelin research guide Stay current on PT-141 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

For research-grade lyophilized PT-141, store powder at -20 degrees Celsius.

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

What is PT-141 used for in research?

-Trp-Lys]-OH What is PT-141? # PT-141, known by its generic name bremelanotide and marketed under the brand name Vyleesi, is a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, with particular relevance to the melanocortin-4 receptor (MC4R) in the central nervous system.

PT-141 binds to and activates multiple melanocortin receptor subtypes: MC1R : Involved in melanogenesis (skin pigmentation) MC3R : Expressed in the hypothalamus, involved in energy balance MC4R : Primary mediator of PT-141's sexual function effects MC5R : Involved in exocrine gland function The MC4R activation in the hypothalamus is the primary mechanism relevant to PT-141's therapeutic effects on sexual desire.

: PT-141 administration produces a small increase in circulating LH, FSH, and testosterone levels, suggesting effects on the hypothalamic-pituitary-gonadal axis This central mechanism means that PT-141 addresses the motivational and desire components of sexual function rather than the peripheral arousal response, making it fundamentally different from treatments like sildenafil or testosterone.

PT-141 (Bremelanotide): Sexual Health Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Where to Find PT-141 Compare all vendor prices → Research-grade suppliers verified by our scoring methodology.

Report an Error Compare PT-141 with Other Peptides PT-141 vs Alprostadil Alprostadil and PT-141 target fundamentally different aspects of sexual dysfunction and are not direct competitors.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 26, 2026 Kisspeptin PT-141 (Bremelanotide) GHK-Cu + 8 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

Relationship to Melanotan-2 # PT-141 is a metabolite of Melanotan-2 (MT-2) and shares structural elements with it.

Peptide Protocol Wiki February 26, 2026 Kisspeptin PT-141 (Bremelanotide) GHK-Cu + 8 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.

Other Research Areas # Hemorrhagic shock : PT-141's parent compound Melanotan-2 and related melanocortin agonists have been studied for hemorrhagic shock due to melanocortin-mediated cardiovascular effects Inflammation : Melanocortin receptors play roles in inflammatory regulation Obesity : MC4R is involved in appetite and energy homeostasis, though PT-141 is not developed for this indication Safety Profile Summary # The safety profile from clinical trials and post-marketing experience shows: Nausea : The most common adverse event (40% of patients), often decreasing with repeated use Flushing : Reported in approximately 20% of patients Headache : Reported in approximately 11% of patients Blood pressure : Transient increases in systolic (1.9 mmHg) and diastolic (1.7 mmHg) blood pressure, resolving within 12 hours Injection site reactions : Mild local reactions at the injection site Hyperpigmentation : Focal darkening of the skin (face, gingiva, breasts) reported in some patients, related to MC1R activation Evidence Gaps and Limitations # Despite FDA approval, several areas remain incompletely characterized: Long-term safety beyond 52 weeks of use Efficacy in postmenopausal women (not studied in Phase 3 tri

ways rather than vascular mechanisms • Derived from Melanotan-2 with improved receptor selectivity • On-demand dosing (administered as needed before anticipated sexual activity) • Unique mechanism distinct from hormonal and PDE5 inhibitor approaches Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved as Vyleesi) 💉 Dosing Amount 1.75 mg Frequency As needed (PRN), at least 45 minutes before anticipated sexual activity Duration Ongoing as needed; no more than 8 doses per month 💊 Administration Route SC Schedule As needed (PRN), at least 45 minutes before anticipated sexual activity Timing At least 45 minutes before anticipated sexual activity; peak plasma at ~1 hour ✓ Rotate injection sites 📅 Cycle Duration Ongoing as needed; no more than 8 doses per month Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Vyleesi auto-injectors should be stored at 20-25 degrees Celsius (68-77 degrees Fahrenheit).

dose: 1.75 mg · cycle: Cycle · reconstitution: reconstitution

Key results from the RECONNECT trials: Statistically significant increases in sexual desire compared to placebo (integrated studies: 0.35 increase, P .001) Statistically significant reductions in distress related to low sexual desire (integrated studies: -0.33, P .001) Effect sizes were modest but clinically meaningful The most common adverse event was nausea (40% bremelanotide vs 1.3% placebo) FDA Approval Details # PT-141 (Vyleesi) was approved on June 21, 2019, with the following label specifications: Indication : Acquired, generalized HSDD in premenopausal women Dose : 1.75 mg subcutaneous injection Administration : Self-administered as needed, at least 45 minutes before anticipated sexual activity Maximum frequency : No more than once every 24 hours, no

dose: 1.75 mg · route: subcutaneous

Confirmed FDA approval for HSDD in premenopausal women On-demand dosing with 1.75 mg SC injection Clinical benefit maintained over treatment period Related Reading # PT-141 research studies and evidence PT-141 dosing protocols PT-141 side effects profile Bivamelagon research guide Gonadorelin research guide Stay current on PT-141 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

dose: 1.75 mg

PMID: 31599840): Pivotal RECONNECT Phase 3 trials demonstrating bremelanotide 1.75 mg SC significantly improves sexual desire and reduces distress in premenopausal women with HSDD compared to placebo.

dose: 1.75 mg

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

PT-141 (Bremelanotide): Sexual Health Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About PT-141 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides PT-141 Reproductive Health Skin & Hair approved PT-141 Also known as: Bremelanotide, Vyleesi, PT141 Compare with 2 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated February 9, 2026 Citations Verified TL;DR PT-141 (Bremelanotide), marketed as Vyleesi, is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan-2.

ways rather than vascular mechanisms • Derived from Melanotan-2 with improved receptor selectivity • On-demand dosing (administered as needed before anticipated sexual activity) • Unique mechanism distinct from hormonal and PDE5 inhibitor approaches Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved as Vyleesi) 💉 Dosing Amount 1.75 mg Frequency As needed (PRN), at least 45 minutes before anticipated sexual activity Duration Ongoing as needed; no more than 8 doses per month 💊 Administration Route SC Schedule As needed (PRN), at least 45 minutes before anticipated sexual activity Timing At least 45 minutes before anticipated sexual activity; peak plasma at ~1 hour ✓ Rotate injection sites 📅 Cycle Duration Ongoing as needed; no more than 8 doses per month Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Vyleesi auto-injectors should be stored at 20-25 degrees Celsius (68-77 degrees Fahrenheit).

Key results from the RECONNECT trials: Statistically significant increases in sexual desire compared to placebo (integrated studies: 0.35 increase, P .001) Statistically significant reductions in distress related to low sexual desire (integrated studies: -0.33, P .001) Effect sizes were modest but clinically meaningful The most common adverse event was nausea (40% bremelanotide vs 1.3% placebo) FDA Approval Details # PT-141 (Vyleesi) was approved on June 21, 2019, with the following label specifications: Indication : Acquired, generalized HSDD in premenopausal women Dose : 1.75 mg subcutaneous injection Administration : Self-administered as needed, at least 45 minutes before anticipated sexual activity Maximum frequency : No more than once every 24 hours, no

The most common treatment-emergent adverse events during the extension were nausea (40.4%), flushing (20.6%), and headache (12.0%).

Other Research Areas # Hemorrhagic shock : PT-141's parent compound Melanotan-2 and related melanocortin agonists have been studied for hemorrhagic shock due to melanocortin-mediated cardiovascular effects Inflammation : Melanocortin receptors play roles in inflammatory regulation Obesity : MC4R is involved in appetite and energy homeostasis, though PT-141 is not developed for this indication Safety Profile Summary # The safety profile from clinical trials and post-marketing experience shows: Nausea : The most common adverse event (40% of patients), often decreasing with repeated use Flushing : Reported in approximately 20% of patients Headache : Reported in approximately 11% of patients Blood pressure : Transient increases in systolic (1.9 mmHg) and diastolic (1.7 mmHg) blood pressure, resolving within 12 hours Injection site reactions : Mild local reactions at the injection site Hyperpigmentation : Focal darkening of the skin (face, gingiva, breasts) reported in some patients, related to MC1R activation Evidence Gaps and Limitations # Despite FDA approval, several areas remain incompletely characterized: Long-term safety beyond 52 weeks of use Efficacy in postmenopausal women (not studied in Phase 3 tri

Demonstrates favorable overall safety profile with primarily mild to moderate adverse events.

Majority of adverse events mild (31%) to moderate (40%) Most common events were nausea, flushing, and headache Tra

Confirmed FDA approval for HSDD in premenopausal women On-demand dosing with 1.75 mg SC injection Clinical benefit maintained over treatment period Related Reading # PT-141 research studies and evidence PT-141 dosing protocols PT-141 side effects profile Bivamelagon research guide Gonadorelin research guide Stay current on PT-141 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the side effects of PT-141?

Reported side effects of PT-141 include nausea, flushing, headache, transient blood pressure increase.

Most reported side effects are mild and transient.

Consult the detailed side effects profile for full information.

Melanotan-2 remains the more pharmacologically diverse compound with broader melanocortin effects including tanning, but its lack of regulatory approval and wider side effect profile reflect its status as an unrefined parent compound.

e assessment essential CBC When: Baseline Why: General health baseline CMP When: Baseline Why: Liver and kidney function (65% renally excreted) Melanocyte assessment (skin exam) When: Baseline Why: MC1R activation can cause focal hyperpigmentation Blood pressure monitoring When: With first few doses Why: Transient BP increase occurs with each dose; verify return to baseline Blood pressure When: Ongoing Why: Transient increases expected; persistent elevation warrants discontinuation ⚠️ Transient increases expected; persistent elevation warrants discontinuation 💡 Key Considerations → Contraindication: Avoid in patients with uncontrolled hypertension or known cardiovascular disease; not for use in postmenopausal women or men (off-label only) Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

e assessment essential CBC When: Baseline Why: General health baseline CMP When: Baseline Why: Liver and kidney function (65% renally excreted) Melanocyte assessment (skin exam) When: Baseline Why: MC1R activation can cause focal hyperpigmentation Blood pressure monitoring When: With first few doses Why: Transient BP increase occurs with each dose; verify return to baseline Blood pressure When: Ongoing Why: Transient increases expected; persistent elevation warrants discontinuation ⚠️ Transient increases expected; persistent elevation warrants discontinuation 💡 Key Considerations → Contraindication: Avoid in patients with uncontrolled hypertension or known cardiovascular disease; not for use in postmenopausal women or men (off-label only) Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

Peptide Protocol Wiki February 17, 2026 Semaglutide BPC-157 Ipamorelin + 6 more Guide 14 min read Peptides for Men's Sexual Health: PT-141, Kisspeptin, and Emerging Options Guide to peptides researched for male sexual health including PT-141, kisspeptin, gonadorelin, HCG, alprostadil, and oxytocin with evidence levels.

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

February 10, 2026 Semaglutide Tirzepatide BPC-157 + 5 more You Might Also Like Related content you may find interesting Peptide Vascular Alprostadil Peptide Skin Melanotan-2 Peptide Reproductive Gonadorelin Peptide Reproductive HCG Table of Contents What is PT-141?

Peptide Protocol Wiki February 26, 2026 Kisspeptin PT-141 (Bremelanotide) GHK-Cu + 8 more Guide 11 min read How to Choose Your First Peptide: A Decision Framework by Goal A comprehensive decision framework to help beginners identify the right peptide for their goals.